Mulugeta Temesgen, Takale Alazar, Umeta Belachew, Terefe Behailu
Department of Clinical Pharmacy, School of Pharmacy, Jimma University, Jimma, Oromia, Ethiopia.
Department of Pharmaceutical Sciences, School of Pharmacy, Jimma University, Jimma, Oromia, Ethiopia.
J Pharm Health Care Sci. 2021 Dec 6;7(1):44. doi: 10.1186/s40780-021-00228-5.
Human immune deficiency virus (HIV) increases the susceptibility to primary infection or reinfection and the risk of tuberculosis (TB) reactivation for patients with latent TB. There was no current report on the rate of active TB infection among HIV-1 infected patients in our teaching and referral hospital. Therefore, this study was aimed to determine the prevalence and factors associated with active TB infection among HIV-1 infected patients.
Hospital-based retrospective cross-sectional study was conducted at the Anti-Retroviral Therapy (ART) chronic follow-up clinic. Systematic random sampling was used to include the patients. A structured questionnaire was used to collect data. Data were analyzed using SPSS version 25. Descriptive statistics were used to describe the findings and multivariate logistic regression was performed to identify factors associated with active TB infection.
150 HIV-1 infected patients (female 54.7%) were included. The median (interquartile range, IQR) age of the patients was 33.5 (25.7, 40.0) years. Twenty-six (17.3%) of the patients had developed active TB infection, which was independently associated with the WHO clinical stage III and IV (AOR: 9.67, 95% confidence interval (CI); 2.21-42.37), p = 0.003). The use of isoniazid preventive therapy (IPT) (AOR: 0.123, 95CI; 0.034-0.44, p = 0.001) and having good adherence to ART medications (AOR: 0.076, 95CI; 0.007-0.80, p = 0.032) was associated with the reduced risk of active TB infection among HIV-1 infected patients.
Advanced WHO clinical stages increased the risk of active TB infection, while the use of IPT and good adherence to ART medications reduced the risk of active TB infection. Therefore, patients with advanced WHO clinical stage should be screened for TB infection, and starting IPT for the candidate patients should be strengthened to reduce the burden of active TB incidence. ART medication adherence should also be supported.
人类免疫缺陷病毒(HIV)会增加潜伏性结核病患者发生原发性感染或再感染的易感性以及结核病复发的风险。目前尚无关于我院教学及转诊医院中HIV-1感染患者活动性结核感染率的报告。因此,本研究旨在确定HIV-1感染患者中活动性结核感染的患病率及相关因素。
在抗逆转录病毒治疗(ART)慢性随访门诊进行基于医院的回顾性横断面研究。采用系统随机抽样纳入患者。使用结构化问卷收集数据。数据采用SPSS 25版进行分析。描述性统计用于描述研究结果,多因素逻辑回归用于确定与活动性结核感染相关的因素。
纳入150例HIV-1感染患者(女性占54.7%)。患者的年龄中位数(四分位间距,IQR)为33.5(25.7,40.0)岁。26例(17.3%)患者发生了活动性结核感染,这与世界卫生组织临床分期III期和IV期独立相关(调整后比值比:9.67,95%置信区间(CI);2.21 - 42.37),p = 0.003)。使用异烟肼预防性治疗(IPT)(调整后比值比:0.123,95%CI;0.034 - 0.44,p = 0.001)以及对ART药物有良好依从性(调整后比值比:0.076,95%CI;0.007 - 0.80,p = 0.032)与HIV-1感染患者活动性结核感染风险降低相关。
世界卫生组织临床分期进展会增加活动性结核感染风险,而使用IPT和对ART药物有良好依从性可降低活动性结核感染风险。因此,应筛查世界卫生组织临床分期进展的患者是否感染结核,对于符合条件的患者应加强启动IPT以减轻活动性结核发病负担。同时也应支持ART药物的依从性。